《Formally cooperate with Southern Gene》
RoJure Medicine and Southern Gene have officially reached a strategic cooperation, ushering in a new era of systematic precision medicine
In 2025, RoJure Medical and Southern Gene officially reached a strategic cooperation agreement. Both sides will jointly promote the research and development and clinical application of multiple technologies around genomics, artificial intelligence, individualized diagnosis and treatment pathways, and digital health management, and jointly build a new ecosystem of precision medicine "from genes to systems".
This collaboration is a crucial part of RoJure Medical's "Defining New Norms for Health" strategic system. RoJure Medical has always positioned itself as an "intelligent physician" brand, dedicated to redefining medical standards with systematic thinking. It not only focuses on the research and development and manufacturing of high-end medical devices but also actively promotes the integration and application of AI, big data, biomaterials, and life sciences. Southern Gene has been deeply engaged in the fields of genetic testing, molecular diagnosis, and bioinformatics for many years, and possesses a solid scientific research foundation and industrialization capabilities. The collaboration between the two sides will open up a full-chain technical channel from "genes to organs, from data to decision-making", providing a strong impetus for the comprehensive upgrade of precision medicine.
According to the cooperation agreement, RoJure Medicine and Southern Gene will focus on joint research and development in the following areas:
Building a multi omics medical database: Leveraging the vast genetic and clinical data resources of Southern Genomics, and combining the technological advantages of flexible medicine in terminal devices and clinical data collection, we jointly construct a high-quality multi omics medical database to empower AI intelligent engines for precise modeling.
Promote individualized diagnosis and treatment pathway design: Both parties will jointly develop an individualized intervention model based on genetic characteristics, lifestyle, and pathological data, optimize the treatment plan recommendation system, and provide patients with a "customized" systematic health management pathway.
Building an integrated health solution platform: Based on the hardware equipment and algorithm capabilities of both parties, jointly develop an integrated diagnosis intervention tracking system that can be widely applied in ICU, rehabilitation, sub-health management and other scenarios, and build a truly closed-loop intelligent medical ecosystem.
RoJure Medical stated that this collaboration is an important extension of the company's "Defining a Healthy New Moment" strategy, marking the upgrade of Flexible Moment from a device manufacturer to a system solution provider. With the deep genetic capabilities of Southern Gene, the company will further enhance the intelligence and individualization level in core products such as ICU systems and micro hyperbaric oxygen chambers. Southern Gene also pointed out that the development of precision medicine has entered a new stage of "scene fusion+system linkage", and relying solely on single point technological breakthroughs is no longer sufficient to meet the complex needs of modern medicine. The advantages of flexible medicine in the construction of medical device systems, AI clinical decision-making, and standardization of data applications will provide important support for both parties to jointly build a practical and replicable precision health management model.
In the future, both sides will continue to expand the dimensions of cooperation, constantly break down the boundaries between technology and medicine, and jointly promote China's precision medicine towards a new stage of systematization, intelligence, and standardization.